Compare Crown Castle International Corp (CCI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs IDEXX Laboratories, Inc. — how do they compare? Crown Castle International Corp trades at $73.82 (market cap $31.33B), while IDEXX Laboratories, Inc. trades at $571.41 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Crown Castle International Corp pays a 5.77% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| CCI | IDXX | |
|---|---|---|
Market Cap | $31.33B | $46.22B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $766.68 |
52-Week Low | $73.61 | $526.44 |
Enterprise Value | $53.69B | $47.12B |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $74.06, up 0.61% today, near a one-year low. The stock shows a bearish technical trend but maintains a 5.5% dividend yield. Recent Q2 2026 earnings beat AFFO estimates, with organic growth of 3.9%, though revenue declined year-over-year. The company completed its transition to a pure-play U.S. tower operator after selling its fiber business.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting 29% upside. Key risks include high debt levels (debt-to-asset ratio of 77.21% in 2025) and competitive pressure in the tower REIT sector. The current valuation appears discounted relative to historical multiples, offering potential for income-focused investors.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
